Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder

Urology

Volumn 76, Issue 4, 2010, Pages 835-840

  Watanabe, Jonathan H ^a   Campbell, Jonathan D ^b   Ravelo, Arliene ^a,b,c,d   Chancellor, Michael B ^c   Kowalski, Jonathan ^d   Sullivan, Sean D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c Beaumont Hospital   (United States)

^d School of Pharmacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCARINIC RECEPTOR BLOCKING AGENT;

ARTICLE; BLADDER RECONSTRUCTION; COST BENEFIT ANALYSIS; HEALTH CARE COST; HUMAN; INTESTINE PERFORATION; NEUROMODULATION; OVERACTIVE BLADDER; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SMALL INTESTINE OBSTRUCTION; TREATMENT OUTCOME;

BOTULINUM TOXIN TYPE A; COSTS AND COST ANALYSIS; ELECTRIC STIMULATION THERAPY; ELECTRODES, IMPLANTED; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAMUSCULAR; MUSCARINIC ANTAGONISTS; PATIENT ACCEPTANCE OF HEALTH CARE; POSTOPERATIVE COMPLICATIONS; PROSTHESIS IMPLANTATION; UNITED STATES; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 77957754446     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.01.080     Document Type: Article

References (30)

1. F. Haab, and D. Castro-Diaz Persistence with antimuscarinic therapy in patients with overactive bladder Int J Clin Pract 59 2005 931 937
2. A.O. D'Souza, M.J. Smith, and L.A. Miller Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan J Manag Care Pharm 14 2008 291 301
3. J. Yeaw, J.S. Benner, and J.G. Walt Comparing adherence and persistence across 6 chronic medication classes J Manag Care Pharm 15 2009 728 740
4. T.J. Greenwell, S.N. Venn, and A.R. Mundy Augmentation cystoplasty BJU Int 88 2001 511 525
5. T.W. Hu, T.H. Wagner, and J.D. Bentkover Estimated economic costs of overactive bladder in the United States Urology 61 2003 1123 1128
6. A. Sisko, C. Truffer, and S. Smith Health spending projections through 2018: recession effects add uncertainty to the outlook Health Aff Millwood 28 2009 w346 w357
7. V. Kalsi, R.B. Popat, and A. Apostolidis Cost-consequence analysis evaluating the use of botulinum neurotoxin-A in patients with detrusor overactivity based on clinical outcomes observed at a single UK Centre Eur Urol 49 2006 519 527
8. K.R. Borman Mastering reimbursement: basics of the surgical package Curr Surg 63 2006 294 296
9. Medtronic Interstim therapy for urinary control, commonly billed codes 2007
10. K. Everaert, W. Kerckhaert, and H. Caluwaerts A prospective randomized trial comparing the 1-stage with the 2-stage implantation of a pulse generator in patients with pelvic floor dysfunction selected for sacral nerve stimulation Eur Urol 45 2004 649 654
11. G. Karsenty, P. Denys, and G. Amarenco Botulinum toxin a (Botox) intradetrusor injections in adults with neurogenic detrusor overactivity/ neurogenic overactive bladder: a systematic literature review Eur Urol 53 2008 275 287
12. Cigna CIGNA healthcare coverage position Subj Botulinum Toxins (Botox A) 2006
13. C.P. Smith, and M.B. Chancellor Simplified bladder botulinum-toxin delivery technique using flexible cystoscope and 10 sites of injection J Endourol 19 2005 880 882
14. L. Beaty A primer for understanding diagnosis-related groups and inpatient hospital reimbursement with nursing implications Crit Care Nurs Q 28 2005 360 369
15. B. Shekarriz, J. Upadhyay, and S. Demirbilek Surgical complications of bladder augmentation: comparison between various enterocystoplasties in 133 patients Urology 55 2000 123 128
16. P.D. Metcalfe, M.P. Cain, and M. Kaefer What is the need for additional bladder surgery after bladder augmentation in childhood? J Urol 176 2006 1801 1805 discussion 1805
17. P.D. Metcalfe, A.J. Casale, and M.A. Kaefer Spontaneous bladder perforations: a report of 500 augmentations in children and analysis of risk J Urol 175 2006 1466 1470 discussion 1470-1471
18. S. Herschorn, and R.J. Hewitt Patient perspective of long-term outcome of augmentation cystoplasty for neurogenic bladder Urology 52 1998 672 678
19. T.W. Hensle, J. Bingham, and J. Lam Preventing reservoir calculi after augmentation cystoplasty and continent urinary diversion: the influence of an irrigation protocol BJU Int 93 2004 585 587
20. M. Brazzelli, A. Murray, and C. Fraser Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: a systematic review J Urol 175 2006 835 841
21. F.N. Burks, A.C. Diokno, and M.J. Lajiness Sacral neuromodulation reprogramming: is it an office burden? Int Urogynecol J Pelvic Floor Dysfunct 19 2008 1137 1140
22. B. Schurch, M. de Seze, and P. Denys Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study J Urol 174 2005 196 200
23. M.R. Gold Cost-Effectiveness in Health and Medicine New York: Oxford University Press 1996 216 219
24. A.C. van Voskuilen, D.J. Oerlemans, and E.H. Weil Long term results of neuromodulation by sacral nerve stimulation for lower urinary tract symptoms: a retrospective single center study Eur Urol 49 2006 366 372
25. U. Jonas, and V. Grunewald New Perspectives in Sacral Nerve Stimulation: for Control of Lower Urinary Tract Dysfunction 2002 Martin Dunitz London 106
26. D.M. Schmid, P. Sauermann, and M. Werner Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics J Urol 176 2006 177 185
27. N. Casanova, E. McGuire, and D.E. Fenner Botulinum toxin: a potential alternative to current treatment of neurogenic and idiopathic urinary incontinence due to detrusor overactivity Int J Gynecol Obstet 95 2006 305 311
28. M.C. Smaldone, and M.B. Chancellor Neuromodulation versus neurotoxin for the treatment of refractory detrusor overactivity: for neurotoxin Nat Clin Pract Urol 5 2008 120 121
29. I. Milsom, P. Abrams, and L. Cardozo How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study BJU Int 87 2001 760 766
30. H.J. Litman, and J.B. McKinlay The future magnitude of urological symptoms in the USA: projections using the Boston Area Community Health survey BJU Int 100 2007 820 825